Clinical trials
Completed Phase 3 trials in the Philippines
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
518 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 10 |
| 2004 | 11 |
| 2005 | 20 |
| 2006 | 36 |
| 2007 | 34 |
| 2008 | 40 |
| 2009 | 35 |
| 2010 | 45 |
| 2011 | 35 |
| 2012 | 34 |
| 2013 | 32 |
| 2014 | 41 |
| 2015 | 18 |
| 2016 | 16 |
| 2017 | 25 |
| 2018 | 10 |
| 2019 | 14 |
| 2020 | 16 |
| 2021 | 7 |
| 2022 | 12 |
| 2023 | 9 |
| 2024 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 518 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 64 |
| GlaxoSmithKline | 61 |
| Novartis Pharmaceuticals | 43 |
| Boehringer Ingelheim | 35 |
| Pfizer | 24 |
| Bayer | 16 |
| Hoffmann-La Roche | 14 |
| Sanofi | 13 |
| Bristol-Myers Squibb | 12 |
| Sanofi Pasteur, a Sanofi Company | 11 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 56 |
| Pulmonary Disease, Chronic Obstructive | 32 |
| Carcinoma, Non-Small-Cell Lung | 26 |
| Asthma | 24 |
| Breast Neoplasms | 21 |
| Influenza, Human | 20 |
| Schizophrenia | 17 |
| Diabetes Mellitus | 16 |
| Epilepsy | 14 |
| Hepatitis B | 14 |
Trials
Showing 1 to 25 of 518. Each trial links to its page on Pharma Observatory.
418 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.